Dr. Reddy's Wins Brazil Clearance For Generic Semaglutide, With Aché As Launch Partner

Brazil's regulator approved the once-weekly diabetes pen in two sizes, and the company puts the country's semaglutide market at about USD 244.6 million.

Share
Dr. Reddy's Wins Brazil Clearance For Generic Semaglutide, With Aché As Launch Partner

Dr. Reddy's Laboratories, the Hyderabad-based drugmaker, said Thursday that Brazil's health regulator ANVISA has granted marketing authorization for its generic semaglutide injection for adults with type 2 diabetes. The company plans to launch the drug in Brazil with Aché.

Two pen sizes, once a week

ANVISA, the National Health Surveillance Agency, cleared the drug for adults whose type 2 diabetes is insufficiently controlled, as an add-on to diet and exercise. It can be used alone when metformin is inappropriate because of intolerance or contraindications, or alongside other diabetes medicines.

The product comes as a pre-filled, multi-dose pen in two presentations, 2 mg/1.5 mL and 4 mg/3 mL, for once-weekly dosing, the company said in its release.

A $244.6 million market

The release says Brazil has 16.6 million adults aged 20 to 79 living with diabetes, sixth most in the world, citing the IDF Diabetes Atlas. Citing IQVIA data through September 2026, the company estimates the country's semaglutide market for diabetes at approximately USD 244.6 million.

MV Ramana, Chief Executive Officer of Global Generics at Dr. Reddy's, said the aim is to widen access "across markets where the patient need is significant," and called Brazil "an important part of that journey." He added: "We plan to launch semaglutide in Brazil with Aché."

Where Brazil fits in the business

Dr. Reddy's makes and sells generics, biosimilars, over-the-counter products and active pharmaceutical ingredients. Global Generics made up 89% of revenue in the year ended March 31, 2026, according to its annual report. Brazil is among the major markets the company lists, alongside the United States, India, Russia and other former Soviet states, China and Europe.

The company's market value was about $12.3 billion as of Thursday morning.

The release calls the approval a step in the company's broader semaglutide strategy, with Aché as its stated launch partner in Brazil.

Sources

More on Dr. Reddy's Laboratories

All Dr. Reddy's Laboratories (RDY) coverage →